|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM317985892 |
| 003 |
DE-627 |
| 005 |
20231225164415.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20201104-05
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1059.xml
|
| 035 |
|
|
|a (DE-627)NLM317985892
|
| 035 |
|
|
|a (NLM)33231696
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ho, Allen C
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes
|b An Analysis of the IRIS Registry
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.11.2021
|
| 500 |
|
|
|a Date Revised 31.05.2022
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2020 Ho, Kleinman, Lum, et al.; licensee SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: Clinical trials in neovascular age-related macular degeneration (nAMD) demonstrate that high visual acuity (VA) can be maintained, and low VA can be improved with anti-vascular endothelial growth factor (VEGF) treatment. Few real-world data investigating the relationship between baseline VA and long-term outcomes exist. This study compares VA at diagnosis and after treatment using data from a large patient registry
|
| 520 |
|
|
|a PATIENTS AND METHODS: Retrospective study of IRIS Registry patients diagnosed with nAMD in one or both eyes between January 2013 and June 2017. Patients received at least two anti-VEGF injections in the study eye(s) less than 45 days apart during the study period. Primary outcomes were the percentage of eyes with 20/40 VA or better at diagnosis and association of VA at diagnosis with longer-term visual outcomes
|
| 520 |
|
|
|a RESULTS: The study included 162,902 eyes. Among all included eyes, 34.3% presented with 20/40 VA or better at diagnosis. Patients with 20/40 vision or better at baseline maintained a mean VA of 20/40 or better for 2 years after treatment initiation
|
| 520 |
|
|
|a CONCLUSIONS: Baseline VA at nAMD diagnosis predicts long-term VA outcomes. Early diagnosis before VA is adversely affected is a key factor in preserving vision in patients with nAMD. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:633-639.]
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
| 650 |
|
7 |
|a Ranibizumab
|2 NLM
|
| 650 |
|
7 |
|a ZL1R02VT79
|2 NLM
|
| 700 |
1 |
|
|a Kleinman, David M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lum, Flora C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Heier, Jeffrey S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lindstrom, Richard L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Orr, Susan C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chang, Grace C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Smith, Eleanor L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pollack, John S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 51(2020), 11 vom: 01. Nov., Seite 633-639
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
| 773 |
1 |
8 |
|g volume:51
|g year:2020
|g number:11
|g day:01
|g month:11
|g pages:633-639
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20201104-05
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 51
|j 2020
|e 11
|b 01
|c 11
|h 633-639
|